Toby Maher

Feat: @TobyMMaher, Justin Oldham MD, and Marlies Wijsenbeek MD Moderaters: @CarlaRCopeland and Ayodeji Adegunsoye MD @ATS_Assemblies

Shoutout to @drcastelino, @tobymmaher, and Dr. Flaherty for leading an amazing discussion at #CHEST2025! Real-world takeaways for real-world care. 📺 Replay available here: bit.ly/FibrosingILDT Thanks to @Boehringer for their educational grant support #CME #MedEd

Watch Toby Maher, MD, MSc, PhD (@TobyMMaher), Flavia Castelino, MD (@drcastelino), and Kevin R. Flaherty, MD, MS discuss clearing the air on fibrosing ILDs at #CHEST2025 – to participate, visit: bit.ly/FibrosingILDT x.com/i/broadcasts/1…

Join Toby Maher, MD, MSc, PhD (@tobymmaher), Flavia Castelino, MD (@drcastelino), and Kevin R. Flaherty, MD, MS, on 10/21 at 6:00 AM CDT during #CHEST2025 for a #fibrosingILD #MedEd event. 🔗 bit.ly/FibrosingILDT #pulmonology

Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade. Congratulations to all our patients & yes, even better drugs are on the way!! Great day for #CureIPF #ScienceMatters fda.gov/drugs/news-eve…

⚡ Up your #fibrosingILD game! Join @PeerView + the experts Drs. Toby Maher (@tobymmaher) & Castelino (@drcastelino) at #CHEST2025 (Oct 21 | 6 AM CDT) for a rapid-fire TownHall on antifibrotics, immunomodulators & emerging therapies. 🫁 👉 bit.ly/FibrosingILDT #MedEd

🚨 Stay ahead in #fibrosingILD care! Join @PeerView with Drs. Maher (@tobymmaher) & Castelino (@drcastelino) at #CHEST2025 on 10/21 at 6 AM CDT for a TownHall on diagnosis, management & emerging therapies. Register: bit.ly/FibrosingILDT #MedEd #pulmonology #ILD

"#FibrosingILD: Conversations on Timely Diagnosis and Antifibrotic Therapy” with Drs. Maher (@tobymmaher) & Castelino (@drcastelino). 10/21 at 6:00 AM CDT. bit.ly/FibrosingILDT #CHEST2025 #pulmonology

What do most clinicians miss about idiopathic pulmonary fibrosis? Find out in the latest episode, where @doctor_saranya speaks with @TobyMMaher about what defines Interstitial Lung Disease, how idiopathic pulmonary fibrosis fits into the picture and more: hubs.la/Q03G8R-W0

Fantastic news for all our patients with IPF who suffer with cough! An overall 43% reduction in cough counts, similar improvement in patient reported cough and benefits seen in 2 weeks. We look forward to the phase 3 study!

When it rains it pours!! What an amazing #ATS2025 for #CurePF4ALL! Nerandomilast -> ⬇️FVC decline compared to placebo in Progressive Pulmonary Fibrosis patients on antifibrotics or untreated. 👏🏼 Drs Maher, Martinez & #FibroneerILD team!! nejm.org/doi/full/10.10…

Wow! What a day for #CureIPF & #ATS2025! First positive drug trial in 10 years in IPF!! Treatment with Nerandomilast -> ⬇️FVC decline compared to placebo in patients on antifibrotics or untreated. Kudos Drs Richeldi and Wijsenbeek and #FibroneerIPF team nejm.org/doi/full/10.10…

Great to see publication of the first positive phase 3 trial in patients with IPF. This represents an important step forward in the treatment of this terrible disease. #cureipf

A reminder to tune in to our session at #ATS2025 on cough in pulmonary fibrosis. Join @TobyMMaher to discuss how new technologies and patient-reported outcomes can address this gap in IPF research. Add to your calendar and join us! calendarlink.com/event/8aCAe #IPF #digitalhealth

#ArtificialIntelligence and the Diagnosis of #InterstitialLungDisease: Are We Ready for ChatMDT?! onlinelibrary.wiley.com/doi/full/10.11… an Editorial by @TobyMMaher on recent research: onlinelibrary.wiley.com/doi/10.1111/re… Follow us on Bluesky: @respirology.bsky.social

Join Strados Labs and @TobyMMaher at #ATS2025 for an engaging session on the often-overlooked symptom of cough in pulmonary fibrosis and ways we can address the gap. May 19, 11:55 AM PST | Exhibitor Hall Innovation Hub #7 We look forward to seeing you there! #IPF

Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non-Responders in IPF? onlinelibrary.wiley.com/doi/10.1111/re… and Editorial by Toby Maher @tobymmaher on recent research: onlinelibrary.wiley.com/doi/10.1111/re… Follow us on Bluesky: @respirology.bsky.social

Fibrosis: cross-organ biology and pathways to development of innovative drugs nature.com/articles/s4157… This new Review highlights core pathways active in fibrotic conditions across organs, and proposes strategies to improve the translation of potential antifibrotic drugs

Join us for the next episode in the specialty series on Tuesday 18 February at 6.30pm! Our panel @R_tattersall, @Sarah_L_Mackie and @TobyMMaher will discuss key updates in rheumatology. Followed by a question and answer session. Book your place now: ow.ly/cLri50UXRCi

@LRSorce @SebastianPalmqv @NiklasMattsson4 @criticcaredoc Most Viewed JAMA 2024: Interstitial Lung Disease 🔗 ja.ma/49HAZ52 @TobyMMaher